Assure Holdings to Acquire Sentry Neuromonitoring

/in /by

Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), is pleased to announce that effective February 24, 2021, it has signed a Term Sheet (“Term Sheet”) to acquire (the “Acquisition”) Sentry Neuromonitoring, LLC (“Sentry”), one of the largest IONM service providers in Texas, for a purchase price of $3,500,000. The purchase price to be paid is $1,225,000 in cash and $2,275,000 in Assure common stock, subject to escrow, TSX Venture Exchange and other requirements.

Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market

/in /by

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of molecular oncology leader Biotheranostics, Inc. for approximately $230 million. Biotheranostics develops and markets two highly differentiated molecular diagnostic tests for breast and metastatic cancers – Breast Cancer Index™ (BCI) and CancerTYPE ID® (CTID).

Butterfly Network, a Global Leader in Democratizing Medical Imaging, Closes Business Combination and Will Begin Trading on the New York Stock Exchange

/in /by

Butterfly Network, Inc. (“Butterfly” or the “Company”) (NYSE: BFLY), an innovative digital health company that is working to democratize medical imaging and contribute to the aspiration of global health equity, today announced that it has completed its business combination with Longview Acquisition Corp. (NYSE: LGVW.U, LGVW, LGVW WS) (“Longview”), a special purpose acquisition company sponsored by an affiliate of Glenview Capital Management, LLC (“Glenview”).

U.S. Diagnostics Firm GenMark Explores Sale Amid Interest

/in /by

GenMark Diagnostics Inc. is exploring a sale after the U.S. firm was approached by potential buyers, according to people familiar with the matter. GenMark is working with a financial adviser as it fields interest from other medical diagnostics companies, the people said, asking not to be identified because the deliberations are private. GenMark competes with companies including Hologic Inc. and Quidel Corp. in the booming medical testing industry. It makes molecular diagnostic equipment to help detect infectious diseases including respiratory pathogens, and for blood culture identification.

Longview Acquisition Corp. Stockholders Approve Business Combination with Butterfly Network, Inc.

/in /by

Longview Acquisition Corp. (NYSE: LGVW.U, LGVW, LGVW WS) , a special purpose acquisition company sponsored by an affiliate of Glenview Capital Management, LLC, announced today that its stockholders voted to approve the proposed business combination with Butterfly Network, Inc. with nearly 100% of the shares of Longview voted at the Special Meeting in favor of the business combination proposal. Founded by Dr. Jonathan Rothberg in 2011, Butterfly has created the world’s first handheld, single-probe whole-body ultrasound system, Butterfly iQ.

Apex Physics Partners Continues Midwest Expansion through Partnership with Advanced Medical Physics

/in /by

Apex Physics Partners (APP), a leading medical physics business services support organization, is proud to announce a new partnership with Advanced Medical Physics (AMP), a leader in diagnostic medical physics services in Indiana. The partnership with Advanced Medical Physics represents the seventh transaction for Apex Physics Partners since inception and the fourth transaction in less than two years of partnership with Blue Sea Capital.

Quidel Weighs Qiagen Deal as Medical M&A Quickens

/in /by

Quidel Corp., the U.S. diagnostics firm, is weighing a combination with Qiagen NV in another sign of ongoing appetite for dealmaking in the medical equipment industry, people with knowledge of the matter said. Quidel, which makes several types of coronavirus tests, has made a preliminary approach to Qiagen to gauge interest in a potential deal, the people said, asking not to be identified discussing confidential information. Deliberations are at an early stage, and there’s no certainty they will result in a deal, the people said.

HORIBA Acquires MedTest DX and Pointe Scientific to Expand Laboratory Chemistry Offerings

/in , /by

HORIBA, Ltd. (Headquarters in Kyoto, Japan, referred to as HORIBA) and HORIBA Instruments (Headquarters in Irvine, California) announced Tuesday that it has acquired MedTest Holdings, Inc. (Headquarters in Canton, MI, USA, composed of MedTest Dx, Inc., Pointe Scientific, Inc., Clinitox Diagnostix, Inc., and Medical Laboratory Solutions, Inc.). The acquisition will combine the complimentary innovative technology offerings of the HORIBA Medical segment (referred to as HORIBA Medical) with MedTest Dx technology, Clinitox, and Pointe Scientific’s R&D and manufacturing capabilities, with particular expertise in FDA 510K and CLIA clearances, to address the multidisciplinary requirements of IVD1 testing customers.

FogChain Announces Definitive Agreement for the Acquisition of Avisa Pharma Inc.

/in /by

FogChain Corp. (CSE: FOG.X) (OTCB: FOGCF) (FRA: MUU3) (the “Company” or “FogChain”) is pleased to announce, further to its news release dated January 13, 2021, the Company has entered into a merger agreement and plan of reorganization (the “Definitive Agreement”) with Avisa Pharma Inc. (“Avisa”) and FogChain USA Inc., a wholly-owned subsidiary of FogChain. Avisa has developed a quantitative, point–of–care diagnostic breath test known as the Avisa BreathTest (“ABT”) for rapidly detecting bacterial pneumonia and pulmonary infections in approximately 10 minutes.

Veracyte to Acquire Decipher Biosciences

/in , /by

Veracyte, Inc. (Nasdaq: VCYT) and Decipher Biosciences, Inc., a commercial-stage precision oncology company focused on urologic cancers, today announced they have entered into a definitive agreement through which Veracyte will acquire Decipher, further solidifying Veracyte’s global leadership in the genomic cancer diagnostics market while accelerating revenue growth.